Daxor Revolutionizes Blood Volume Testing with New Facility Partnership

Daxor's Expansion into Midwest Healthcare Facilities
Premier 735-Bed Healthcare Facility Implements ezBVA Lab Service to Enhance Cardiovascular Outpatient Care
Oak Ridge, TN - Daxor Corporation (Nasdaq: DXR), a leader in blood volume measurement technology, is proud to announce its expansion into a major Midwest healthcare facility. This initiative aims to enhance cardiovascular outpatient care by integrating Daxor’s advanced blood volume analysis (BVA) testing directly into the hospital's services.
This 735-bed medical campus is set to embrace state-of-the-art blood volume analysis, effectively transforming the way fluid management is handled for patients suffering from heart failure, hypertension, and other significant cardiovascular conditions. By ensuring that patients receive swift and precise testing, Daxor aims to improve outcomes through meticulous fluid management.
ezBVA Lab Service Benefits
The outpatient program will streamline blood testing by expediting samples to the ezBVA Lab located in Tennessee. As a CLIA-certified facility, the lab ensures that comprehensive BVA results will be available within just 24 hours. This rapid turnaround allows healthcare providers to make informed decisions quickly, leading to better patient care.
“Precise volume management is at the heart of effective cardiovascular care, and this expansion continues to widen the ezBVA footprint in the Midwest,” stated Michael Feldschuh, Daxor’s CEO and President. He emphasized that the diagnostic’s 98% accuracy empowers clinicians to deliver personalized fluid management solutions that not only enhance patient outcomes but also help in reducing healthcare costs.
Cost Efficiency and Accessibility
Crucially, the ezBVA Lab service is designed to provide healthcare facilities access to Daxor's cutting-edge technology without imposing any capital expenditure. This capability enables hospitals to enhance their services while ensuring full reimbursement through standard CPT codes for both inpatient and outpatient settings available under public and private insurance plans.
The Impact of Daxor's Technology
Daxor's commitment to blood volume measurement technology has placed it at the forefront of healthcare innovation. The company has developed the BVA-100, a significant breakthrough that is the only diagnostic blood test cleared by the FDA to provide safe, accurate, and objective quantification of blood volume status and composition compared to patient-specific norms.
To date, Daxor has conducted over 65,000 tests at leading hospitals across the United States, greatly contributing to improved hospital performance in various medical and surgical conditions. The use of BVA technology has notably decreased mortality and readmission rates in patients battling heart failure and in critical care situations.
Future Directions and Research
Daxor is continually seeking to advance healthcare practices. The company is actively involved in conducting multiple trials focused on heart failure treatment, receiving support from the NIH. Furthermore, Daxor is collaborating with the U.S. Department of Defense to refine analyzers aimed at improving combat casualty care.
About Daxor Corporation
Daxor Corporation (Nasdaq: DXR) is dedicated to advancing healthcare by providing innovative blood volume testing technology. The company envisions optimal blood volume management for all patients, driving its mission to enable superior fluid management solutions.
For further information about Daxor and its pioneering technology, visit their website. Additionally, stakeholders can sign up to receive the latest updates on Daxor’s innovations.
Frequently Asked Questions
What is the purpose of Daxor's expansion into the Midwest?
Daxor's expansion aims to integrate blood volume analysis services into a major healthcare facility, enhancing cardiovascular outpatient care.
What does the ezBVA Lab service offer?
The ezBVA Lab service allows for rapid blood volume analysis with results delivered within 24 hours, improving patient management.
How does Daxor’s technology benefit patients?
Daxor’s technology ensures precise fluid management, which is crucial for patients with cardiovascular issues, ultimately improving health outcomes.
Is Daxor's service covered by insurance?
Yes, Daxor’s services are fully reimbursable through established CPT codes under both public and private insurance plans.
How has Daxor contributed to healthcare improvement?
Over 65,000 BVA tests performed have significantly reduced readmission rates and improved performance metrics across various medical conditions.
About The Author
Contact Logan Wright privately here. Or send an email with ATTN: Logan Wright as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.